Daily Hot Plays

[QuicKtip]

$AIMD is pleased to announce that its groundbreaking VELDONA® formulation has been granted an invention patent in Taiwan and has filed for global patent protection under the Patent Cooperation Treaty (PCT). https://finance.yahoo.com/news/ainos-secures-taiwan-invention-patent-123000316.html

[QuicKtip]

$CBDW GET IN EARLY!! HEARING HUGE NEWS/UPDATE COMING VERY SOON...

[QuicKtip]

$UNCY announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the Virtual Life Sciences Investor Forum on Thursday, September 19, 2024 at 2:00 p.m. ET in New York, NY. https://finance.yahoo.com/news/unicycive-therapeutics-present-virtual-life-110300237.html

[ProfitScout]

$MVCO News: Metavesco and Local Choice Spirits Announce Joint Venture to Launch Limited Edition Bourbon Series

CUMMING, GA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Metavesco, Inc. (OTC PINK:MVCO) is excited to announce the formation of a joint venture with award-winning Local Choice Spirits to launch a new limited-edition bourbon series at the historic Striped Pig Distillery, Charleston’s first distillery steeped in history back to 1838! The partnership follows an initial Letter of Intent for an acquisition, but market conditions in the over-the-counter (OTC) market have prompted a strategic shift toward this collaborative venture.

In this joint initiative, Metavesco has purchased 8-year-old barreled aged bourbon from Local Choice Spirits, laying the foundation for a premium bourbon line that combines the expertise of both companies. Together, they will develop a unique brand concept, leveraging Local Choice Spirits' acclaimed production capabilities. Additionally, Local Choice Spirits will provide licensing and distribution, enabling swift and efficient entry into key markets.

“We’re excited to shift gears and explore this new partnership with Local Choice Spirits,” said Ryan Schadel, CEO of Metavesco. “The opportunity to collaborate with such a respected name in the spirits industry allows us to introduce a high-quality product to our audience while capitalizing on Local Choice’s distribution expertise.”

Local Choice Spirits, known for crafting award-winning spirits and pushing the boundaries of innovation in the beverage industry, is thrilled to bring their resources and experience to this joint venture.

Paula “Pixie” Dezzutti commented, “The combination of rarity, quality, respect, collaboration, and local craftsmanship creates an attractive opportunity for the passionate MVCO shareholders to tie in with Local Choice’s artisanal narrative leading to future large-scale releases. An 8-year-old bourbon signals commitment to quality, developing complex flavors from the oak barrels marrying into the whiskey. The Metavesco/Local Choice Spirits partnership signals the same commitment to strengthening the bond between these two niche innovators.”

The joint venture is expected to bring this rare, small batch limited-edition bourbon to market before year end, with more details on branding and availability to be released soon.

About Metavesco

Metavesco is a web3 enterprise and digital asset innovator. The Company has bitcoin mining operations at hosted facilities in KY and IA. Through its wholly owned subsidiary, the Company operates Boring Brew, a specialty coffee company utilizing owned and licensed NFT IP as unique packaging.

About Local Choice and Striped Pig Distillery

The award-winning Striped Pig Distillery is a woman-owned, family-run, community-driven business, since 2010 marking its tenure as Charleston’s oldest distillery. Striped Pig helped revive the distillery scene in Charleston when it opened its doors in North Charleston in 2013, becoming the holy city’s first distillery since Prohibition. Its origin story is one of ‘great curiosity’ and a nod to some tongue-in-cheek US history, brought to life by their beloved Striped Pig mascot, Jackson. Since those early days, the Pig has continued its support of the community, expanded its lineup, received numerous accolades and awards, and has kept driving the distillery scene in Charleston and the wider industry forward with firsts, like the Bottled in Bond Bourbon release and launching the first bourbon on the blockchain.

Striped Pig Distillery is located at 2225-A Old School Drive Charleston, SC 29405

For more information about the distillery, Tours and Tastings, visit: http://www.stripedpigdistillery.com/ To purchase spirits online: https://stripedpigdistillery.com/shop/

Safe Harbor Statement

This press release contains statements that constitute forward-looking statements. These statements appear in a number of places in this press release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is included in the Company's filings on otcmarkets.com.

CONTACT:
[e-mail]
[phone]

[QuicKtip]

$CBDW 1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company https://finance.yahoo.com/news/1606-corp-signs-letter-intent-120000809.html

[QuicKtip]

$DFCO just signed a €260K contract with Onet Group for heat pump installations in Spain, opening doors to more opportunities across France and Spain. Major move in expanding their European footprint!

Keep an eye on this one: https://dalrada.com/dalrada-signs-contract-with-france-based-onet-group-for-heat-pump-installation-in-light-industrial-facility

#SmallCaps #Growthstock

[ProfitScout]

$YGMZ News: MingZhu Logistics to Acquire HOLDCO 36 in Transformational Business Combination

SHENZHEN, China, Sept. 12, 2024 /PRNewswire/ -- MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced the acquisition of HOLDCO 36 in a transformational business combination. The closing of the all-stock acquisition is subject to customary closing conditions, including regulatory approvals.

Mr. Jinlong Yang, Chairman and Chief Executive Officer of MingZhu, commented, "As part of our active M&A process, we have evaluated a series of potential transactions, with regard to long-term potential, valuation, and alignment with building shareholder value. We are excited about the proposed acquisition of HOLDCO 36 because it would immediately transform our business into higher growth, burgeoning market segments with a favorable regulatory environment and underlying demand catalysts. Upon successful deal closure and integration, we would expect to see a meaningful creation of value for all shareholders."

For assets and projects being injected, parties are with explicit understanding that the projects contributed by HOLDCO 36 and their conditions may change but new projects are always being secured and developed to either be added or be replacing non-active ones. Initial business assets and operations being acquired are expected to include:

Green Fuel Smart Trading Platform: A comprehensive global distribution platform for biofuels, natural gas, hydrogen-based fuels, methanol, and related equipment. This platform aims to establish itself as the OPEC of green biofuels, facilitating the trade and distribution of sustainable fuel sources worldwide.
EPC+O: Engineering, Procurement, Construction, and Operations for biomass energy, and new energy systems such as wind, solar, storage, hydrogen, and ammonia EPC engineering productions systems. Using the existing ECaaS to provide distributed biomass "carbon-electricity-biomass energy" co-generation solutions. The business provides wind, solar, storage, green hydrogen, and green ammonia and green fuel EPC consulting services to clients in Americas, Asia, Africa and Europe.

Power Leasing and Energy: Developed an intelligent financial service platform for sales and lease financing for green and lightweight vessels, maritime equipment and lightweight materials for vessels.

Digital Energy Services Segment for the Steel Industry: Innovating a smart virtual power plant for closed-loop virtual scenarios targeting steel mills worldwide, supporting local distributed energy operations and usage. Managing national zero-carbon industrial parks for the steel industry and voluntary carbon reduction, which provides carbon credit, supply chain carbon verification, green certificate trading and verification.

About MingZhu Logistics Holdings Limited (Nasdaq: YGMZ)

Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets. For more information, please visit http://ir.szygmz.com.

Forward-Looking Statements

The statements in this press release regarding the Company's future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words "may", "will", "want", "should", "believe", "expect", "anticipate", "estimate", "calculate" or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company's strategic objectives, the Company's future plans, market demand and user acceptance of the Company's products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company's reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China's macroeconomic conditions, and the risks and assumptions disclosed in the Company's reports provided to the CSRC (China Security Regulatory Commission). The potential acquisition involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including but not limited to statements about the potential benefits of the potential acquisition; the anticipated timing of closing of the potential acquisition (including failure to obtain necessary regulatory approvals) and the possibility that the potential acquisition does not close; risks related to the ability to realize the anticipated benefits of the potential acquisition, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the potential acquisition making it more difficult to maintain business and operational relationships; negative effects of announcing the potential acquisition or the consummation of the potential acquisition on the market price of our common stock or operating results; costs associated with the potential acquisition; unknown liabilities; and the risk of litigation and/or regulatory actions related to the potential acquisition. For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company's relevant SEC filings for additional factors that may affect the Company's future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances.

https://c212.net/c/img/favicon.png?sn=CN05051&sd=2024-09-12 View original content:https://www.prnewswire.com/news-releases/mingzhu-logistics-to-acquire-holdco-36-in-transformational-business-combination-302246593.html

SOURCE MingZhu Logistics Holdings Limited

[QuicKtip]

$CBDW 1606 Corporation Forges Ahead with Strategic Stake in Adnexus https://allcapresearch.com/penny-stocks/f/1606-corporation-forges-ahead-with-strategic-stake-in-adnexus

[QuicKtip]

$CBDW 1606 Corp: Pioneering AI Chatbots in CBD and Investor Relations https://allcapresearch.com/f/cbdw-pioneering-ai-chatbots-in-cbd-and-investor-relations

[QuicKtip]

$AIMD Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

[QuicKtip]

$DYAI Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership https://finance.yahoo.com/news/dyadic-international-inc-proliant-health-123000731.html @chazzsheen3

[Singhania]

Big News - $ACON announced the launch of a program to establish a statewide network of providers in New Jersey to implement Nociscan for the personal injury and workers' compensation population.

https://www.nasdaq.com/press-release/aclarion-launches-surgeon-partnership-apply-nociscans-ai-technology-personal-injury

[QuicKtip]

$VINO Gaucho Holdings' Algodon Fine Wines Expands U.S. Distribution Network With Pasanella & Son Vintners https://finance.yahoo.com/news/gaucho-holdings-algodon-fine-wines-170000340.html

[Singhania]

$ACON is now oversold with RSI at 30. The stock is due for a bounce and there seems to be no major hurdle before $0.35. So risk/reward is clearly in favor of buyers and I would not be surprised if we can see the recovery in coming sessions.

[QuicKtip]

$CBDW 1606 Corp’s Strategic Plans for Q3 2024: Spotlight on the NIBA Show in Florida
https://cbdw.ai/1606-corps-strategic-plans-for-q3-2024-spotlight-on-the-niba-show-in-florida/

[QuicKtip]

#BREAKINGNEWS: $AMPG AmpliTech Group’s AGTGSS Division To Participate At Mobile World Congress Shows in Las Vegas And Barcelona To Market Its Comprehensive Private 5G End-to-End Solution for Businesses and Homes https://finance.yahoo.com/news/amplitech-group-agtgss-division-participate-130000431.html @chazzsheen3

[ProfitScout]

$GNPX News: Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Intends to Create Two Distinct Businesses, Re-Focusing Genprex on its Oncology Clinical Development Program

New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes

AUSTIN, Texas, Sept. 4, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its intention to transfer the Company's diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary ("NewCo"). NewCo would focus on developing and commercializing GPX-002, a diabetes gene therapy drug candidate for the treatment of Type 1 (T1D) and Type 2 diabetes (T2D).

"Genprex's diabetes program has received the attention of several potential investors, partners, collaborators and pharmaceutical companies, and we believe separating it from our oncology programs could help increase interest, expedite clinical development and unlock the value of our novel diabetes program," said Ryan Confer, President and Chief Executive Officer at Genprex. "The new subsidiary would be positioned to be a pure-play diabetes-focused biopharmaceutical company, while Genprex would be a pure-play oncology-focused biopharmaceutical company. This contemplated separation of entities could enable potential direct investment and strategic collaboration into the advancement of the diabetes program. Diabetic patients are in need of advanced therapies, and we believe GPX-002 holds the potential for disease modification for long-term effectiveness, which could directly impact the global diabetes epidemic."

The planned spin-out transaction would allow both Genprex and NewCo to enhance each company's focus on meeting the needs of their respective markets, patients and stakeholders. The spin-out, if completed as presently contemplated, would result in NewCo focusing on developing GPX-002, while Genprex would retain its oncology clinical development programs and other oncology pipeline assets. The decision to pursue the reorganization demonstrates Genprex's strong ongoing commitment to the Company's streamlined, focused strategies and ongoing research and development prioritization initiative. The potential formation and transfer of the clinical development program into the wholly-owned subsidiary is currently anticipated to occur by the end of 2024, subject to adequate financing, the satisfaction of customary conditions and final approval from the Genprex management and Board of Directors.

The Company's goal for separating the diabetes clinical development program from its oncology program follows closely behind Genprex's recent announcement to re-focus its oncology clinical development program for streamlined, expeditious regulatory submission of its lead oncology drug candidate, Reqorsa® Gene Therapy. As previously announced, the Company continues to evaluate ways to optimize its clinical and research programs and operational strategies. Additionally, the Company is considering various strategic alternatives and opportunities to enhance stockholder value.

GPX-002, which has been exclusively licensed from the University of Pittsburgh, is being developed using the same construct for the treatment of both T1D and T2D. The same general novel approach is used in each of T1D and T2D whereby an adeno-associated virus (AAV) vector containing the Pdx1 and MafA genes is administered directly into the pancreatic duct. In humans, this can be done with a routine endoscopy procedure. The diabetes product candidates are currently being evaluated and optimized in preclinical studies at the University of Pittsburgh.

"With the potential to address the entire diabetes market, we believe our gene therapy approach would position NewCo as an innovator in emerging diabetes therapies," continued Confer. "The most significant advancement in the treatment of diabetes happened more than 100 years ago when insulin was first introduced to treat T1D patients. We believe our treatment has the potential to disrupt the diabetes market by replacing the daily burden of blood glucose monitoring and insulin replacement therapy, as well as the need for GLP-1 treatments in T2D."

About GPX-002 and Diabetes

In T1D, GPX-002 is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In vivo, preclinical studies show that GPX-002 restored normal blood glucose levels for an extended period of time.

In February 2023, research collaborators at the University of Pittsburgh presented preclinical data in a NHP model of Type 1 diabetes highlighting the therapeutic potential of GPX-002 at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) in Berlin, Germany.

The statistically significant study results showed the treated animals had:

Decreased insulin requirements
Increased c-peptide levels
Improved glucose tolerance compared to baseline
In April 2023, Genprex hosted a Key Opinion Leader virtual event entitled "Novel Gene Therapy to Treat Type 1 Diabetes," which discussed preclinical data reported at ATTD 2023 supporting gene therapy to treat T1D. Watch the KOL event here.

In a similar approach for T2D, GPX-002 (formerly known as GPX-003), where autoimmunity is not at play, is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.

According to the U.S. Center for Disease Control as of 2024, 38.4 million Americans, or approximately 11.6% of the U.S. population, have diabetes. It is also believed that more than 97 million Americans aged 18 years or older have prediabetes. In 2021, approximately 537 million adults (20-79 years) worldwide were living with diabetes, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million in 2045. Also in 2021, diabetes caused more than 6.7 million deaths globally and diabetes resulted in approximately $966 billion dollars in health expenditures, a 316% increase over the preceding fifteen years.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the potential separation of its diabetes clinical development program, including the anticipated benefits of the internal reorganization, the expected timing of the reorganization and/or if it is completed as contemplated or at all; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its short-term and long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
[e-mail]

GNPX Media Contact
Kalyn Dabbs
[e-mail]


https://c212.net/c/img/favicon.png?sn=DA97213&sd=2024-09-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-announces-plans-to-launch-separate-company-to-focus-on-the-development-of-gene-therapy-to-treat-type-1-and-type-2-diabetes-302237871.html

SOURCE Genprex, Inc.

[deri21]

$CBDW 1606 Corp. Signs Letter of Intent to Acquire a Strategic Stake in Adnexus, a Leading AI Biotech Company
https://finance.yahoo.com/news/1606-corp-signs-letter-intent-120000809.html

[QuicKtip]

$DYAI Entered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbumin https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html

[QuicKtip]

$AIMD is pleased to announce that its groundbreaking VELDONA® formulation has been granted an invention patent in Taiwan and has filed for global patent protection under the Patent Cooperation Treaty (PCT). https://finance.yahoo.com/news/ainos-secures-taiwan-invention-patent-123000316.html

[QuicKtip]

$CBDW Investors should stay tuned as the company continues to execute its vision and attract market attention. https://allcapresearch.com/f/1606-corp-cbdw-breaks-key-resistance-with-massive-volume-surge

[ProfitScout]

$GNPX News: Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes

AUSTIN, Texas, Sept. 3, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in September 2024.


Event: H.C. Wainwright 26th Annual Global Investment Conference
Conference Dates: September 9-13, 2024
Presentation Date: On-demand September 9-11, 2024 in the conference portal (virtual)
Presenter: Ryan Confer, Genprex's President, Chief Executive Officer and Chief Financial Officer

Mr. Confer will virtually deliver an overview of the Company's pioneering gene therapies for cancer and diabetes and will be available for virtual meetings with investors through the conference platform.

Event: Chardan's 8th Annual Genetic Medicines Conference
Dates: September 30 – October 1, 2024
Location: Westin Grand Central in New York, NY
Company Participant: Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing

Mr. Gallagher will be available for in-person meetings with conference attendees.

For those interested in meeting Genprex management during these conferences, please request a meeting through the conference portal or reach out to Investor Relations at [e-mail].

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
[e-mail]

GNPX Media Contact
Kalyn Dabbs
[e-mail]

https://c212.net/c/img/favicon.png?sn=DA96104&sd=2024-09-03 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-and-participate-at-upcoming-september-investor-and-industry-conferences-302236356.html

[QuicKtip]

#BreakingNews: $AMPG AmpliTech Group’s Bookings Surpass $1M In August 2024

In Addition To Above Bookings, Spectrum Semiconductor Materials Division Completes $700K Single Sale Transaction During The Week of August 26th 2024

https://finance.yahoo.com/news/amplitech-group-bookings-surpass-1m-130000053.html

#nasdaq #stockstowatch #stockstobuy #AMPG @charles

[QuicKtip]

$AIMD - Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

AI Nose now has a 79% accuracy in identifying 761 samples across 22 VOCs in Japanese semiconductor manufacturing factories

AI Nose can be integrated into robotics systems in smart factories, serving as the digital nose of AI technology

https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

#nasdaq #stockstowatch #stockstobuy #AIMD @charles

[deri21]

$RITE CEO will attend the National Investment Bankers Association meeting next week in Ft. Lauderdale. RITE looks to engage investment bankers to facilitate future planned capital raises and to help tell RITE’s story.
https://x.com/Mineralrite/status/1829549139459441053

[QuicKtip]

$CBDW 1606 Corp’s Strategic Plans for Q3 2024: Spotlight on the NIBA Show in Florida https://cbdw.ai/1606-corps-strategic-plans-for-q3-2024-spotlight-on-the-niba-show-in-florida/

[QuicKtip]

$AIMD AI Nose now has a 79% accuracy in identifying 761 samples across 22 VOCs in Japanese semiconductor manufacturing factories https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

[QuicKtip]

$DYAI Entered into a joint development agreement with a Top 10 global dairy company for the development of non-animal alpha-lactalbumin https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html

[QuicKtip]

$CBDW 1606 Corp CEO with Key Highlights from Recent Redchip Interview https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview

[ProfitScout]

$GDHG News: Golden Heaven Group Holdings Ltd. Secures Plot in Yangzhou's Yunhe Sanwan Scenic Spot for New Amusement Complex and Extends Strategic Partnership with Dacheng Culture

NANPING, China, Aug. 27, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. ("Golden Heaven" or the "Company") (Nasdaq: GDHG), an amusement park operator in China, today announced that it was granted the land use rights for an approximately 26,000-square-meter plot (the "Plot") located in Yunhe Sanwan Scenic Spot in Yangzhou, Jiangsu Province, China on August 16, 2024 by Yangzhou Lemandi Tourism Development and Investment Co., Ltd. The Company plans to launch a new recreation and amusement complex at this site, with commercial operations anticipated to begin in October 2024.

Situated within the Yunhe Sanwan Scenic Spot, which is geographically close to the Beijing-Hangzhou Grand Canal, the world's longest man-made waterway, the Plot offers substantial advantages. By securing the land use rights in such a popular tourist attraction of significant historical and cultural importance, as well as a location with high foot traffic, the Company anticipates growth opportunities to be derived from introducing innovative amusement rides to enhance the park's appeal and competitiveness in the market.

This development marks the second collaboration between the Company and Nanping City Dacheng Culture Communication Co., Ltd., ("Dacheng Culture") in co-developing attraction projects. The two parties have signed a one-year collaboration agreement (the "Agreement") valued at RMB1.2 million on August 19, 2024. Under the Agreement, Golden Heaven agrees to lease certain land and property to Dacheng Culture for activities such as wedding photography, traditional costume photography, and various celebratory events. In return, Dacheng Culture agrees to pay to the Company an aggregate lease payment of RMB1.2 million, over the term of the Agreement, which extends from August 19, 2024 to August 18, 2025.

Mr. Jin Xu, CEO and Chairman of the Company, commented, "We are thrilled to have obtained the land use rights for this plot within the Yunhe Sanwan Scenic Spot. Located in a bustling area of Yangzhou with beautiful surroundings and high foot traffic, it is an ideal destination for tourists, families and young couples. Our goal is to create an amusement park that seamlessly integrates entertainment and leisure experiences with a variety of cultural activities."

Mr. Xu added, "The continued partnership with Dacheng Culture is a testament to the win-win alliance between two industry leaders. By synergizing the unique advantages, resources and innovative capabilities of both sides, we will not only enhance the cultural depth and entertainment value of our park but also expand our market influence. We look forward to working with Dacheng Culture to write a new chapter for the cultural tourism and leisure entertainment industry of the city."

About Golden Heaven Group Holdings Ltd.

The Company is an offshore holding company incorporated in the Cayman Islands with no material operations of its own. Through its Chinese operating entities, the Company manages and operates amusement parks, water parks and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.

Forward-Looking Statements

This press release contains "forward-looking statements". Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "could," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "propose," "potential," "continue" or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

Golden Heaven Group Holdings Ltd.
Email: [e-mail]

Ascent Investor Relations LLC
Phone: [phone]
Email: [e-mail]

https://c212.net/c/img/favicon.png?sn=CN91507&sd=2024-08-27 View original content:https://www.prnewswire.com/news-releases/golden-heaven-group-holdings-ltd-secures-plot-in-yangzhous-yunhe-sanwan-scenic-spot-for-new-amusement-complex-and-extends-strategic-partnership-with-dacheng-culture-302230780.html

SOURCE Golden Heaven Group Holdings Ltd.

[QuicKtip]

$AIMD AI Nose journey begins in healthcare and is now expanding into smart factories https://finance.yahoo.com/news/ainos-ceo-highlights-ai-nose-123000685.html

[QuicKtip]

$DYAI Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and Biologicals https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html

[BlazingStocks]

$BHAT - Originally an entertainment company, Blue Hat is now focusing on innovations in the commodity trading arena. The company is planning to integrate artificial intelligence to enhance its offerings, including an intelligent gold supply chain and recycling system, as well as a sophisticated gold derivatives trading platform.
https://www.globenewswire.com/en/news-release/2024/08/15/2930903/0/en/Blue-Hat-Expands-into-Gold-Trading-with-Strategic-Partnerships-As-Gold-Prices-Rise-Amid-Economic-Optimism.html

[ProfitScout]

$NRXP News: HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

$30 million Term Sheet from qualified lender for non-dilutive financing for first clinic acquisitions; anticipated closing within 60 days

Executed Non-Binding Term Sheet with initial clinic partners generating annual revenue of over $10 million, with additional partners to be selected under this initial funding agreement

Company projects annualized revenues of $100 million through continued acquisition by mid 2025

Additional information to be presented at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024

MIAMI, Aug. 26, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("HOPE," the "Company"), a medical and technology driven company, today announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, the Company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. The Company anticipates potential operations in the United States, France, and the United Kingdom.

The non-dilutive acquisition funding announced today is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange.

Ketamine is increasingly used to treat suicidal depression, treatment resistant depression (TRD) and Post Traumatic Stress Disorder (PTSD). Until now there has been no unified entity organized around delivering consistent outpatient care for suicidal depression, TRD and PTSD that combines pharmaceutical therapy, FDA approved and proven medical technologies such as Transcranial Magnetic Stimulation (TMS), digital therapeutics and access to clinical trial protocols for the newest potential treatments, delivered by properly licensed medical professionals to optimize care of people with these conditions. Collectively, these conditions represent a crisis that results in the death of someone around the globe every minute. HOPE aims to bring a unified, patient-centric and science-based approach to the care of patients and their families.

"HOPE is dedicated to providing an accessible platform to help caregivers address the critical needs of those suffering from suicidal thoughts, TRD, PTSD and related challenges. We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care and demonstrate best-practices for mental health professionals around the world," said Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "These clinics, and others under review, are planned to provide the foundation for a network generating revenue of approximately $100 million annually in the coming year."

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-potential-acquisition-and-financing-agreements-for-30-million-in-currently-operating-interventional-psychiatry-clinics-302230157.html

SOURCE NRx Pharmaceuticals, Inc.

[QuicKtip]

$VINO announced the appointment of David Reinecke to the Company's Board of Directors effective August 16, 2024. https://finance.yahoo.com/news/strategic-appointment-underscores-commitment-leveraging-160000371.html

[QuicKtip]

$AIMD AI Nose now has a 79% accuracy in identifying 761 samples across 22 VOCs in Japanese semiconductor manufacturing factories https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

[QuicKtip]

$AMPG announced the signing of a Memorandum of Understanding (MOU) with a USA based IP Data Networking company to deploy a Private 5G Network in the state of California. https://finance.yahoo.com/news/amplitech-group-agtgss-division-signs-123000765.html

[QuicKtip]

$CBDW Ambitious Growth Targets https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview

[BlazingStocks]

$BHAT - Blue Hat Interactive Entertainment Technology is emerging as a key player in gold trading due to their recent business cooperation agreement with Sichuan Jinyinghe Industrial Co., Ltd. in Shenzhen, GTC Group LLC in Dubai and its subsidiary, Golden Alpha Strategy Ltd., has been granted Dealers in Precious Metals and Stones Category A Registration by Hong Kong Customs and Excise Department.
https://www.globenewswire.com/en/news-release/2024/08/15/2930903/0/en/Blue-Hat-Expands-into-Gold-Trading-with-Strategic-Partnerships-As-Gold-Prices-Rise-Amid-Economic-Optimism.html

[QuicKtip]

$CBDW New blog is out! https://x.com/CBDWInc/status/1826281331606909070

[QuicKtip]

$AIMD Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024 https://finance.yahoo.com/news/ainos-participate-fireside-chat-water-120000950.html

[QuicKtip]

$VINO Gaucho Group Holdings, Inc. Expands Argentine Offerings With Algodon Extra Virgin Olive Oil https://finance.yahoo.com/news/gaucho-group-holdings-inc-expands-133000388.html

[QuicKtip]

$AMPG announced the company will host an investor conference call on Wednesday, August 28th, 2024 at 5:00 PM ET. https://finance.yahoo.com/news/amplitech-group-hold-q2-2024-133000215.html

[QuicKtip]

$JETR Star Jets aims to expand its clientele base, offering exclusive and tailored travel solutions that meet the unique demands of affluent individuals and corporate clients. https://finance.yahoo.com/news/star-jets-international-otc-jetr-125000390.html

[QuicKtip]

$AMPG announced the company will host an investor conference call on Wednesday, August 28th, 2024 at 5:00 PM ET. https://finance.yahoo.com/news/amplitech-group-hold-q2-2024-133000215.html

[QuicKtip]

$AIMD AI Nose can be integrated into robotics systems in smart factories, serving as the digital nose of AI technology https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

[QuicKtip]

$CBDW AI Chatbot: Leading the Way in Investor Relations https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview

[QuicKtip]

$AIMD today announced that its AI Nose has made a significant breakthrough in factory automation with 79% accuracy in detecting 761 samples across 22 different volatile organic compounds (VOCs). https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

[QuicKtip]

$CBDW 1606 Corp is well-positioned to achieve its target of ten ISO partnerships by the end of 2024, which will significantly enhance its market presence and investor appeal. https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview

[QuicKtip]

$CBDW 1606 Corp is well-positioned to achieve its target of ten ISO partnerships by the end of 2024, which will significantly enhance its market presence and investor appeal. https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview